5204602349_c87b204860_z

FDA commissioner Scott Gottlieb says that more rigorous approval process would be unique to opioids

pharmafile | November 12, 2018 | News story | Sales and Marketing FDA, Gottlieb, opioid crisis, opioids 

Food and Drug Administration (FDA) commissioner Scott Gottlieb has said that if a more rigorous approval process is introduced for opioids, the higher standards will be ‘unique’ to opioids.

“I don’t think this same kind of standard would apply in other therapeutic areas. I think opioids are unique,” Gottlieb said.

The suggestion comes in the midst of a debate as to whether new drugs should be approved or rejected within the context of what is already available on the market. Although currently, drugs are approved only on the basis as to whether the medicine is safe and effective, this could change in regards to opioids.

Advertisement

The change may mean that new opioids would have to bring some distinct value to the market in order to be approved.

Gottlieb added: “I would do everything that I could from a policy standpoint … to make it explicit that this was narrowly tailored to opioids for public health reasons”

Louis Goss

Related Content

Johnson & Johnson submits robotic surgical system for De Novo classification

Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …

MedPharm announces US FDA inspection of North Carolina manufacturing facility

MedPharm has announced that the US Food and Drug Administration (FDA) has completed a successful …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

The Gateway to Local Adoption Series

Latest content